122 related articles for article (PubMed ID: 11142480)
1. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.
Axdorph U; Sjöberg J; Grimfors G; Landgren O; Porwit-MacDonald A; Björkholm M
Ann Oncol; 2000 Nov; 11(11):1405-11. PubMed ID: 11142480
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma.
Zanotti R; Trolese A; Ambrosetti A; Nadali G; Visco C; Ricetti MM; Benedetti F; Pizzolo G
Ann Oncol; 2002 Dec; 13(12):1908-14. PubMed ID: 12453859
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Ann Oncol; 1992 Sep; 3 Suppl 4():49-52. PubMed ID: 1333270
[TBL] [Abstract][Full Text] [Related]
4. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival.
Christiansen I; Enblad G; Kälkner KM; Gidlöf C; Glimelius B; Tötterman TH
Leuk Lymphoma; 1995 Oct; 19(3-4):243-51. PubMed ID: 8535215
[TBL] [Abstract][Full Text] [Related]
5. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.
Nadali G; Tavecchia L; Zanolin E; Bonfante V; Viviani S; Camerini E; Musto P; Di Renzo N; Carotenuto M; Chilosi M; Krampera M; Pizzolo G
Blood; 1998 Apr; 91(8):3011-6. PubMed ID: 9531614
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function.
Axdorph U; Porwit-MacDonald A; Sjöberg J; Grimfors G; Ekman M; Wang W; Biberfeld P; Björkholm M
Br J Cancer; 1999 Dec; 81(7):1182-7. PubMed ID: 10584880
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.
Sarris AH; Kliche KO; Pethambaram P; Preti A; Tucker S; Jackow C; Messina O; Pugh W; Hagemeister FB; McLaughlin P; Rodriguez MA; Romaguera J; Fritsche H; Witzig T; Duvic M; Andreeff M; Cabanillas F
Ann Oncol; 1999 Apr; 10(4):433-40. PubMed ID: 10370786
[TBL] [Abstract][Full Text] [Related]
8. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
10. Soluble molecules as biological markers in Hodgkin's disease.
Nadali G; Vinante F; Chilosi M; Pizzolo G
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():99-105. PubMed ID: 9570686
[TBL] [Abstract][Full Text] [Related]
11. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era.
Wang Q; Qin Y; Zhou S; He X; Yang J; Kang S; Liu P; Yang S; Zhang C; Gui L; Sun Y; Shi Y
Oncotarget; 2016 Nov; 7(44):72219-72228. PubMed ID: 27750215
[TBL] [Abstract][Full Text] [Related]
13. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.
Franklin J; Paulus U; Lieberz D; Breuer K; Tesch H; Diehl V
Ann Oncol; 2000 May; 11(5):617-23. PubMed ID: 10907959
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.
Gause A; Jung W; Keymis S; Schobert I; Scholz R; Schmits R; Diehl V; Pohl C; Hasenclever D; Pfreundschuh M
Leuk Lymphoma; 1992 Aug; 7(5-6):439-47. PubMed ID: 1283546
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
[TBL] [Abstract][Full Text] [Related]
17. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy.
Visco C; Vassilakopoulos TP; Kliche KO; Nadali G; Viviani S; Bonfante V; Medeiros LJ; Notti P; Rassidakis GZ; Peethambaram P; Wilder R; Witzig T; Gianni M; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Leuk Lymphoma; 2004 Oct; 45(10):2085-92. PubMed ID: 15370254
[TBL] [Abstract][Full Text] [Related]
20. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
